AstraZeneca PLC (AZNCF)
- Previous Close
140.30 - Open
135.35 - Bid --
- Ask --
- Day's Range
135.35 - 135.35 - 52 Week Range
118.16 - 152.06 - Volume
401 - Avg. Volume
3,054 - Market Cap (intraday)
215.813B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
36.78 - EPS (TTM)
3.68 - Earnings Date --
- Forward Dividend & Yield 2.86 (2.04%)
- Ex-Dividend Date Feb 22, 2024
- 1y Target Est
--
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZNCF
Related Videos: AZNCF
Performance Overview: AZNCF
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZNCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZNCF
Valuation Measures
Market Cap
215.72B
Enterprise Value
238.48B
Trailing P/E
35.52
Forward P/E
16.05
PEG Ratio (5yr expected)
0.86
Price/Sales (ttm)
4.61
Price/Book (mrq)
5.36
Enterprise Value/Revenue
5.21
Enterprise Value/EBITDA
17.77
Financial Highlights
Profitability and Income Statement
Profit Margin
13.00%
Return on Assets (ttm)
6.60%
Return on Equity (ttm)
15.64%
Revenue (ttm)
45.81B
Net Income Avi to Common (ttm)
5.95B
Diluted EPS (ttm)
3.68
Balance Sheet and Cash Flow
Total Cash (mrq)
5.86B
Total Debt/Equity (mrq)
75.70%
Levered Free Cash Flow (ttm)
9.5B
Company Insights: AZNCF
AZNCF does not have Company Insights
Research Reports: AZNCF
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, global oil inventories face future; feeling the internet's backbone; and initiating coverage of Qualys; and Lithium Americas, Bausch & Lomb and Macy's.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.